Earnings

AbbVie’s Dual-Target Drug Shows Phase 2 Results for Hard-to-Treat Crohn’s Disease

Oct 19, 2026 · 04:05 AM ET· updated 48m ago

AbbVie (NYSE:ABBV) today announced that its investigational ABBV-466, a novel dual-targeting therapy against IL-23 p19 and integrin α4β7, demonstrated higher rates of endoscopic remissiona at Week 12 than either

Why It Matters

AbbVie tested a new medicine for Crohn's disease in early patients. The medicine worked better than expected, which suggests it might help sick people if it passes more tests.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ABBV286.88

+3.48 (+1.23%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.